PPARG and type 2 diabetes mellitus: Although weak or moderate, the PPARγ activity of 1a e 1i is not to be underestimated in that the well-known metaglidasen, having EC50 and Emax around 10 μM and 10% respectively, is still investigated as a useful agent for the treatment of T2DM and hyperglycemia, as demonstrated by some recent patents46,47.